Study (year) |
Microarray type (probes [n]) |
Samples included |
Main objective |
Main findings |
Ref. |
Dhanasekaran et al. (2001) |
cDNA array (10K) |
14 PC, 20 CRPC, 13 BPH, 9 NAP |
Molecular classification |
Molecular signature for PC. PIM1 and hepsin as prognostic markers for PSA recurrence |
[29] |
Luo et al. (2001) |
cDNA array (6.5K) |
16 PC, 9 BPH |
Molecular classification |
Molecular signature for PC |
[16] |
Magee et al. (2001) |
Affymetrix Hu6800 (7K) |
11 PC, 4 NAP |
Molecular classification |
Molecular signature for PC |
[17] |
Welsh et al. (2001) |
Affymetrix U95a (8.9K) |
23 PC, 1 LNM, 9 NAP |
Molecular classification |
Molecular signature for PC |
[26] |
LaTulippe et al. (2002) |
Affymetrix U95 (63K) |
23 PC, 9 MPC, 3 nonmalignant |
Molecular classification |
Molecular signature for PC |
[24] |
Singh et al. (2002) |
Affymetrix U95Av2 (12.6K) |
52 PC, 50 NAP |
Molecular classification and prognostic markers |
5-gene signature for PSA recurrence. 29-gene signature for Gleason score prediction. Gene signatures for prediction of normal vs cancer |
[18] |
Best et al. (2003) |
cDNA array (6.4K) |
13 PC, 13 NAP (pooled) |
Molecular classification |
Molecular classification of moderate- vs high-grade PC (21-gene signature) |
[19] |
Henshall et al. (2003) |
Affymetrix Eos Hu03 (60K) |
72 PC |
Prognostic markers |
Cox proportional hazards survival analysis applied to microarray expression data identified Trp-p8 as marker for PSA recurrence |
[106] |
*Ashida et al. (2004) |
cDNA array (23K) |
20 PC, 10 HG-PIN |
Molecular classification |
Molecular signature for HG-PIN to PC transition |
[23] |
Glinsky et al. (2004) |
Affymetrix U95Av2 (12.6K) |
79 PC |
Prognostic markers |
Three 4-/5-gene signatures for prediction of PSA recurrence, which combined into a single predictor algorithm improved the accuracy of a clinical nomogram for recurrence prediction |
[10] |
Lapointe et al. (2004) |
cDNA array (26.3K) |
62 PC, 9 LNM, 41 NAP |
Molecular classification |
Clinically relevant subgroups of PC by unsupervised clustering. MUC1 and AZPG1 as prognostic markers for PSA recurrence |
[30] |
Stuart et al. (2004) |
Affymetrix U95Av2 (12.6K) |
88 prostate tissue samples scored for relative content of PC, BPH and stromal cells |
Molecular classification |
Deliniation of cell type-specific expression profiles for PC cells, BPH cells, and PC-associated stromal cells by a new mathematical in silico dissection approach |
[107] |
Yu et al. (2004) |
Affymetrix U95 (37.7K) |
66 PC, 60 NAP, 23 N |
Prognostic markers |
70-gene tumor aggressiveness predictor signature. 11-principal components model for classification of normal vs cancer |
[37] |
Halvorsen et al. (2005) |
cDNA array (40K) |
29 PC, 23 NAP |
Molecular classification |
Molecular signature for PC. Multigene model for normal vs cancer classification |
[21] |
*Kristiansen et al. (2005) |
cDNA array (4K) |
42 PC, 42 NAP |
Molecular classification |
Molecular signature for PC. CD24 and CD166/MEMD as prognostic markers for PSA recurrence |
[20] |
Stephenson et al. (2005) |
Affymetrix U133A (22.3K) |
79 PC |
Prognostic markers |
Two logistic regression models for prediction of PSA recurrence. An integrated 'nomogram plus gene signature' model with improved predictive power compared with the clinical nomogram alone |
[11] |
*True et al. (2006) |
cDNA array (7.7K) |
121 PC (Gleason pattern 3, 4, or 5) and matched NAP cells from 59 individuals |
Molecular classification |
Molecular signatures for PC and Gleason grade. 86-gene signature for prediction of low- vs high-grade PC |
[22] |
*Richardson et al. (2007) |
Affymetrix U133 plus 2.0 (54K) |
5 matched PC, NAP, benign stroma and PC-associated stroma cell populations |
Molecular classification |
Molecular signature for PC and PC-associated stroma |
[108] |
*Tamura et al. (2007) |
cDNA array (7.7K) |
25 CRPC, 10 HSPC cell populations from 18 and 10 individuals, respectively |
Molecular classification |
Molecular signature for CRPC by unsupervised clustering |
[32] |
*Tomlins et al. (2007) |
cDNA array (20K) |
101 cell populations (PC, CRPC, BPH, N, PIA, PIN and stroma) from 44 individuals |
Bioinformatic modelling |
An integrative molecular concept map model of PC progression from normal epithelium to CRPC |
[31] |
*Knight et al. (2008) |
cDNA array (32K) |
5 matched basal and luminal prostate epithelial cell populations from BPH patients |
Molecular classification |
TEAD1 and c-Cbl as prostate basal cell markers and prognostic markers for survival |
[42] |
Thorsen et al. (2008) |
Affymetrix HuEx 1.0 ST (229K) |
15 PC, 10 NAP |
Molecular classification |
Molecular signature for PC. Identification of PC-specific mRNA splice variants |
[109] |
*Dakhova et al. (2009) |
Agilent (41K) |
17 matched reactive stroma (grade 3) and benign stroma cell populations from PC patients |
Molecular classification |
Molecular signature of PC-associated reactive stroma. Identification of deregulated pathways in reactive stroma by gene ontology analysis |
[101] |
Comments